Lipocine is a specialty pharmaceutical company focused on developing innovative oral treatment alternatives for use in men’s and women’s health using its proprietary drug delivery technologies. Lipocine product development pipeline entails repositioning of established drugs with significantly improved patient compliance through an efficient 505(b) (2) regulatory pathway strategy.
LPCN 1021 is an oral testosterone replacement product candidate with positive topline Phase 3 efficacy results and is currently in an ongoing safety extension phase. The product is targeted to treat symptoms of low testosterone for hypogonadal men in need of testosterone replacement therapy. We believe LPCN 1021 is a safer alternative to current non-orals; reliably restores and maintains testosterone levels; is more convenient than currently marketed products and has the potential to improve patient’s therapy, adherence and retention.
LPCN 1111 is a novel next generation oral testosterone product candidate currently in Phase 2 with successful demonstration for once daily oral dosing for testosterone replacement therapy.
LPCN 1107 is targeted to be the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and is currently in Phase 1.